VLP Therapeutics, Fujifilm ink pact for COVID vaccine
Tokyo: Fujifilm Holdings Corp said on Thursday that it had signed a manufacturing contract agreement with U.S.-based firm VLP Therapeutics for a Covid-19 vaccine formulation.
Japan's Fujifilm will use its manufacturing facilities and infrastructure to handle the development of the vaccine for clinical trials, the two companies said in a statement.
VLP's RNA-based vaccine candidate was selected for funding by the Japan Agency for Medical Research and Development.
The biotech firm has a Japanese subsidiary which is involved in drug research with government bodies and universities.
Fujifilm has been increasingly shifting into healthcare over the past decade from its traditional photography and office solutions businesses.
Last month, it concluded a successful Phase-3 clinical trial of its Avigan drug for use in Covid-19 patients.
A Fujifilm unit is also involved in making ingredients for Novavax Inc's coronavirus vaccine candidate.
Read also: Serum Institute Covid-19 vaccine to be made available by end of January 2021: Sharad Pawar
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd